Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570713 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00570713 is a Phase 2 study that has completed, run by Morphotek. The registered enrollment target is 155 participants.
The verdict
NCT00570713, a Phase 2 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG MORAb-009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570713
The ClinicalTrials.gov registry entry for NCT00570713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00570713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570713 about?
NCT00570713 is a clinical study titled "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer". The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
What is the current status of trial NCT00570713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2007-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00570713?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), MORAb-009 (DRUG).
Who is sponsoring clinical trial NCT00570713?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.